E. Coli Bronchiectasis Treatment Guidelines

Acute Exacerbation Treatment

The European Respiratory Society recommends treating E. coli bronchiectasis exacerbations with 14 days of antibiotics, selected based on antibiotic susceptibility testing from sputum culture, for all patients regardless of the causative organism 1, 2, 3
The European Respiratory Society guidelines establish 14 days as the standard duration for treating all acute bronchiectasis exacerbations, regardless of the causative organism, with evidence showing significant improvements in sputum volume, bacterial clearance, C-reactive protein, incremental walk test, and quality of life scores 1

For E. coli specifically, select antibiotics according to susceptibility patterns, commonly fluoroquinolones, amoxicillin-clavulanate, or trimethoprim-sulfamethoxazole depending on resistance patterns 1
Extend treatment beyond 14 days only if the patient has not returned to baseline clinical state by day 14, and re-evaluate clinically and obtain new sputum culture at this point 1
Shorter courses (<14 days) may be considered only for mild exacerbations in patients with mild disease, or patients with rapid return to baseline state, but evidence supporting shorter courses is lacking 1

Oral antibiotics are first-line for most exacerbations, but switch to intravenous antibiotics for severe exacerbations, treatment failures after oral therapy, or if the patient is acutely deteriorating 4, 6
If the patient experiences ≥3 exacerbations per year with E. coli, consider long-term prophylactic antibiotics, such as oral macrolides (azithromycin or erythromycin), after optimizing airway clearance techniques 3, 7